2016 Networking Safety 
European Pharmaceutical Review
DECEMBER 14, 2023
Over the past few years, we have researched the types of evidence used in regulatory decisions for drug product withdrawals due to safety concerns in Europe. Our research showed that in Europe between 1999 and 2016, 35 products were withdrawn. But over time, trends in what evidence is most available and therefore most used, change.
European Pharmaceutical Review
JULY 20, 2022
Withdrawing drugs over safety concerns requires careful analysis of the health benefits and risks by regulators. Monitoring and studying the side effects of licensed medicines is an essential part of drug development to ensure public safety. Six products were withdrawn or revoked for safety reasons during the study period.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MAY 20, 2024
5,6 Clinical trials are essential for the safety and efficacy of novel therapies to be established. In fact, one-quarter of rare disease trials between 2016 and 2020 were terminated due to low accrual rates. References European Commission. Public Health – Rare Diseases. Available at: [link] Wakap, et al.
European Pharmaceutical Review
JULY 5, 2022
The drug is recognised in several international clinical guidelines for use as monotherapy or combination treatment regimens for advanced gastric cancer, including the European Society for Medical Oncology (ESMO), 2 the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). 5): V38-V49. Oncotarget.
Referral MD
MAY 19, 2023
Blockchain technology addresses patients’ and medical staff’s need for secure data recording, transmission, and consultation over networks. In 2016, US healthcare fraud cost $30 million. Blockchain will improve healthcare safety and transparency. Personalized medicine and wearables raise data protection concerns.
Pharma Marketing Network
MAY 15, 2023
Additionally, by analyzing data from completed clinical trials, companies can gain insights into the safety and effectiveness of their products, which can inform the development of new drugs. 1 (2016) 3. The post The Use of Big Data in Pharmaceutical Marketing: Opportunities and Challenges appeared first on Pharma Marketing Network.
European Pharmaceutical Review
SEPTEMBER 22, 2023
7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed. She is currently CEO and successfully led the IPO on Nasdaq in 2016.
Expert insights. Personalized for you.
116 
Let's personalize your content